Pfizer is facing three class actions that allege the pharmaceutical company improperly obtained a patent covering its arthritis drug Celebrex (celecoxib) and used it to force generic drug makers into settlements that delay their entry into the market, Law360 has reported.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, Celebrex, antitrust
